A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus, encoding for the tumor associated antigen (TAA) carcinoembryonic antigen (CEA), with potential antineoplastic activity. Upon administration, ALVAC-CEA vaccine expresses CEA and may stimulate a host immune response against tumor cells expressing CEA. This may result in the inhibition of tumor growth and/or metastasis. CEA is overexpressed in a variety of tumor cell types. Check for active clinical trials using this agent. OR A cancer vaccine made with a form of the canarypox virus that does not cause disease in people. It is being studied in the treatment of some kinds of cancer. The virus is changed in the laboratory to make a protein called carcinoembryonic antigen (CEA), which is a tumor marker. ALVAC-CEA vaccine may help the immune system find and kill cancer cells that make CEA.